

Cell line name	DRICUi007-A
----------------	-------------

Purpose

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

In compliance with donor signed consent forms, users of the Cardiff/IPMAR iPS cell lines are required to obtain and have in place all relevant ethical approvals in advance of any approved research project being undertaken. Use of Cardiff/IPMAR iPS cell lines as provided is strictly restricted to research of neurodegenerative disorders only, and no permissions are granted for any use of the cell lines outside of the use stated in the CLIP. Animal use is not permitted for this Cardiff/IPMAR iPS cell line, which includes, but is not limited to, xenotransplantation of the iPSC or derived cells into animals.

Third Party Obligations: IP or license provisions

This EBiSC Cell line was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan, Inc. ("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp.

Publication

All third party publications in relation to the Cardiff/IPMAR iPS cell lines are required to acknowledge "The UKDRI IPMAR Research Group" within the list of authorships, and must include in the publication the names of all individuals belonging to The UKDRI IPMAR Research Group. The full list of IPMAR author names and affiliations can be found on GitHub using the following web address: https://github.com/A-Castillo/IPMAR/blob/main/IPMAR_affiliations.txt.

Cell line name

DRICUi007-A

Limited use label License No: 518 CytoTune™ Technology for Products

Notice to Purchaser: This product is authorized for reprogramming methods that involve or pertain to the preparation of iPS cells or related cells. The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of product to perform internal use and for educational purposes. No right to resell this product or any of its components, or iPS cells or related cells generated by use of the product, or derivatives thereof (hereafter “the Materials”) is conveyed expressly, by implication, or by estoppel. For clarity, purchasers have the right to use third party service providers for generating iPS cells and derivatives for the benefit of such purchasers. Purchasers can deposit the Materials with not-for-profit repositories (“Repositories”) and transfer cells to not-for-profit research entities (not affiliated with a for-profit organization) for their internal research. Such recipient Repositories and not-for-profit research entities are allowed to distribute the Materials not-for financial gain to other users for their internal research. If the Materials are transferred to other users in accordance with the terms of this label license accompanying the product (hereafter “Label License”), the transferring party should notify recipients of such Materials of these terms by transferring a copy of the Label License to the recipients. To obtain commercial rights for the sale of the Materials or for a fee-for-service generation of the Materials other than as allowed in paragraph 1 above, purchasers are requested to contact Dनावेक Corporation at cytotune@dnavec-corp.com. For all other commercial applications relating to the use of the Materials, purchasers might be required to contact iPS Academia Japan. Customers may contact iPS Academia Japan either directly at license@ips-ac.co.jp or through Dनावेक Corporation.

Data Processing

The Personal Data which can be Processed in view of this EAU are

- | | |
|--|---------------------------|
| • Genetic Data including STR profiles: | Yes |
| • Clinical Data | Yes - disease status only |
| • Biometric Data | Yes - sex and ethnicity |
| • Other | No |

The categories of the Data Subjects to which the Personal Data relate that are Processed are

- | | |
|----------------------|-----|
| • Study participants | Yes |
| • Other | No |

The nature and the purpose of the Processing of the Personal Data are as follows: Collecting / storing / analysing / sharing Personal data for generation / characterisation / qualification / use / distribution of iPS lines / and iPS derivatives.

Cell Line Information Pack (CLIP)



Cell line name

DRICUi007-A

Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement:

"The EBiSC Bank acknowledges the IPMAR research group as the source of the human induced pluripotent cell line DRICUi007-A which was generated with support from the Medical research Council, the UK Dementia Research Institute and the EBiSC2 project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement n°115582 and from the IMI-2 JU under grant agreement N°821362, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."

SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

User acknowledgement

Please sign below to indicate that you have read and acknowledge the information contained in this CLIP.

Name _____

Position _____

Signature _____

Date _____



In case of queries, please [get in touch via: Contact@EBiSC.org](mailto:Contact@EBiSC.org)